$MRK

Terns Pharmaceuticals, Inc.

CIK:0000310158|SEC Filings
v3.25.4
Consolidated Statement of Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]      
Sales $ 65,011 $ 64,168 $ 60,115
Costs, Expenses and Other      
Cost of sales 16,382 15,193 16,126
Selling, general and administrative 10,733 10,816 10,504
Research and development 15,789 17,938 30,531
Restructuring costs 889 309 599
Other (income) expense, net 151 (24) 466
Total costs, expenses and other 43,944 44,232 58,226
Income Before Taxes 21,067 19,936 1,889
Taxes on Income 2,804 2,803 1,512
Net Income 18,263 17,133 377
Less: Net Income Attributable to Noncontrolling Interests 9 16 12
Net Income Attributable to Merck & Co., Inc. $ 18,254 $ 17,117 $ 365
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 7.30 $ 6.76 $ 0.14
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 7.28 $ 6.74 $ 0.14